Inhibitors of the ERK Mitogen-Activated Protein Kinase Cascade for Targeting RAS Mutant Cancers

Enzymes

Volumn 34, Issue , 2013, Pages 67-106

  Gentry, Leanna ^a   Samatar, Ahmed A ^b   Der, Channing J ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

MEK; Protein kinase inhibitors; Raf; Small GTPase

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE INHIBITOR; RAS PROTEIN;

ANIMAL; ARTICLE; DRUG ANTAGONISM; GENETICS; HUMAN; MEK; METABOLISM; MUTATION; NEOPLASM; RAF; SMALL GTPASE;

MEK; PROTEIN KINASE INHIBITORS; RAF; SMALL GTPASE;

ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; NEOPLASMS; RAS PROTEINS;

EID: 84887227181     PISSN: 18746047     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-420146-0.00004-4     Document Type: Chapter

References (89)

1. Cox A.D., Der C.J. Ras history: the saga continues. Small GTPases 2010, 1(1):2-27.
2. Flaherty K.T., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 2010, 363(9):809-819.
3. Chapman P.B., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011, 364(26):2507-2516.
4. Hauschild A., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380(9839):358-365.
5. Flaherty K.T., et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 2012, 367(2):107-114.
6. Sullivan R.J., Flaherty K.T. Resistance to BRAF-targeted therapy in melanoma. Eur. J. Cancer 2013, 49(6):1297-1304.
7. Akinleye A., et al. MEK and the inhibitors: from bench to bedside. J. Hematol. Oncol. 2013, 6:27.
8. Coles L.C., Shaw P.E. PAK1 primes MEK1 for phosphorylation by Raf-1 kinase during cross-cascade activation of the ERK pathway. Oncogene 2002, 21(14):2236-2244.
9. Park E.R., Eblen S.T., Catling A.D. MEK1 activation by PAK: a novel mechanism. Cell. Signal. 2007, 19(7):1488-1496.
10. Skarpen E., et al. MEK1 and MEK2 regulate distinct functions by sorting ERK2 to different intracellular compartments. FASEB J. 2008, 22(2):466-476.
11. Ussar S., Voss T. MEK1 and MEK2, different regulators of the G1/S transition. J. Biol. Chem. 2004, 279(42):43861-43869.
12. Roskoski R. ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol. Res. 2012, 66(2):105-143.
13. Romeo Y., Zhang X., Roux P.P. Regulation and function of the RSK family of protein kinases. Biochem. J. 2012, 441(2):553-569.
14. Huang C.Y., Tan T.H. DUSPs, to MAP kinases and beyond. Cell Biosci. 2012, 2(1):24.
15. Pages G., et al. Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science 1999, 286(5443):1374-1377.
16. Yao Y., et al. Extracellular signal-regulated kinase 2 is necessary for mesoderm differentiation. Proc. Natl. Acad. Sci. U.S.A. 2003, 100(22):12759-12764.
17. Shin S., et al. ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol. Cell 2010, 38(1):114-127.
18. Qin J., Xin H., Nickoloff B.J. Specifically targeting ERK1 or ERK2 kills melanoma cells. J. Transl. Med. 2012, 10:15.
19. Blasco R.B., et al. c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 2011, 19(5):652-663.
20. Karreth F.A., et al. C-Raf is required for the initiation of lung cancer by K-Ras(G12D). Cancer Discov. 2011, 1(2):128-136.
21. Eser S., et al. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell 2013, 23(3):406-420.
22. Solit D.B., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439(7074):358-362.
23. Duncan J.S., et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012, 149(2):307-321.
24. Heidorn S.J., et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140(2):209-221.
25. Poulikakos P.I., et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011, 480(7377):387-390.
26. Hatzivassiliou G., et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature 2013, 501(7466):232-236.
27. Gould G.W., et al. The activation of distinct mitogen-activated protein kinase cascades is required for the stimulation of 2-deoxyglucose uptake by interleukin-1 and insulin-like growth factor-1 in KB cells. Biochem. J. 1995, 311(Pt 3):735-738.
28. Favata M.F., et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 1998, 273(29):18623-18632.
29. Lorusso P.M., et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J. Clin. Oncol. 2005, 23(23):5281-5293.
30. Sebolt-Leopold J.S., et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med. 1999, 5(7):810-816.
31. Rinehart J., et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 2004, 22(22):4456-4462.
32. Yoshida T., et al. Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2. Oncotarget 2012, 3(12):1533-1545.
33. Gilmartin A.G., et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin. Cancer Res. 2011, 17(5):989-1000.
34. Infante J.R., et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012, 13(8):773-781.
35. Kim K.B., et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J. Clin. Oncol. 2013, 31(4):482-489.
36. Su F., et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 2012, 366(3):207-215.
37. Yeh T.C., et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin. Cancer Res. 2007, 13(5):1576-1583.
38. Davies B.R., et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol. Cancer Ther. 2007, 6(8):2209-2219.
39. Banerji U., et al. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin. Cancer Res. 2010, 16(5):1613-1623.
40. Robert C., et al. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol. 2013, 14(8):733-740.
41. Catalanotti F., et al. Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. Clin. Cancer Res. 2013, 19(8):2257-2264.
42. Janne P.A., et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013, 14(1):38-47.
43. O'Neil B.H., et al. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 2011, 29(17):2350-2356.
44. Selumetinib shows promise in metastatic uveal melanoma. Cancer Discov. 2013, 3(7):OF8.
45. Kim K., et al. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br. J. Haematol. 2010, 149(4):537-549.
46. Heist R.S., et al. Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial. J. Clin. Oncol. 2013, 31(15). (suppl.; abstr 2530).
47. Macarulla T., et al. Phase I/II study of FOLFIRI plus the MEK1/2 inhibitor pimasertib (MSC1936369B) as second-line treatment for KRAS mutated metastatic colorectal cancer. Ann. Oncol. 2012, 23(4):27.
48. Verslype C., et al. Pimasertib plus gemcitabine in metastatic pancreatic adenocarcinoma: results of a safety run-in part of a phase II trial 2013.
49. Yoon J., Koo K.H., Choi K.Y. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res. 2011, 71(2):445-453.
50. Martinelli E., et al. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Int. J. Cancer 2013, 133:2089-2101.
51. Domann F.E., Mitchen J.M., Clifton K.H. Restoration of thyroid function after total thyroidectomy and quantitative thyroid cell transplantation. Endocrinology 1990, 127(6):2673-2678.
52. Choo E.F., et al. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions. Drug Metab. Dispos. 2012, 40(5):919-927.
53. Choo E.F., et al. PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts. Cancer Chemother. Pharmacol. 2013, 71(1):133-143.
54. Wong H., et al. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clin. Cancer Res. 2012, 18(11):3090-3099.
55. Baudy A.R., et al. FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973. EJNMMI Res. 2012, 2(1):22.
56. Lorusso P.M., et al. A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors 2012.
57. Barrett S.D., et al. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg. Med. Chem. Lett. 2008, 18(24):6501-6504.
58. Henderson Y.C., et al. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol. Cancer Ther. 2010, 9(7):1968-1976.
59. Hennig M., et al. Targeting mitogen-activated protein kinase kinase with the inhibitor PD0325901 decreases hepatocellular carcinoma growth in vitro and in mouse model systems. Hepatology 2010, 51(4):1218-1225.
60. Torti V.R., et al. Epithelial tissue hyperplasia induced by the RAF inhibitor PF-04880594 is attenuated by a clinically well-tolerated dose of the MEK inhibitor PD-0325901. Mol. Cancer Ther. 2012, 11(10):2274-2283.
61. LoRusso P.M., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin. Cancer Res. 2010, 16(6):1924-1937.
62. Boasberg P.D., et al. Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer. Cancer Chemother. Pharmacol. 2011, 68(2):547-552.
63. Haura E.B., et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin. Cancer Res. 2010, 16(8):2450-2457.
64. Iverson C., et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res. 2009, 69(17):6839-6847.
65. Chang Q., et al. Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts. BMC Cancer 2010, 10:515.
66. Liu D., et al. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. Int. J. Cancer 2010, 127(12):2965-2973.
67. Weekes C.D., et al. Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer 2011.
68. Lim H.Y., et al. A phase II trial of MEK inhibitor BAY 86-9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma (HCC) 2012.
69. Cohen R.B., et al. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. Eur. J. Cancer 2013, 49(7):1521-1529.
70. Dong Q., et al. Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer. Bioorg. Med. Chem. Lett. 2011, 21(5):1315-1319.
71. von Euw E., et al. Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol. Cancer 2012, 11:22.
72. Dahlman K.B., et al. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov. 2012, 2(9):791-797.
73. Adjei A.A., et al. Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors 2013.
74. Finn R.S., et al. A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer 2012.
75. Ascierto P.A., et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013, 14(3):249-256.
76. Kirkwood J.M., et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin. Cancer Res. 2012, 18(2):555-567.
77. Gibney G.T., Weber J.S. Expanding targeted therapy to NRAS-mutated melanoma. Lancet Oncol. 2013, 14(3):186-188.
78. Ishii N., et al. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. Cancer Res. 2013, 73(13):4050-4060.
79. Martinez-Garcia M., et al. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Clin. Cancer Res. 2012, 18(17):4806-4819.
80. Isshiki Y., et al. Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent. Bioorg. Med. Chem. Lett. 2011, 21(6):1795-1801.
81. Lee L., et al. The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of CH4987655 in healthy volunteers: target suppression using a biomarker. Clin. Cancer Res. 2009, 15(23):7368-7374.
82. Leijen S., et al. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. Clin. Cancer Res. 2012, 18(17):4794-4805.
83. Goto M., et al. E6201 [(3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7 (8H)-dione], a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)-1 and MEK kinase-1: in vitro characterization of its anti-inflammatory and antihyperproliferative activities. J. Pharmacol. Exp. Ther. 2009, 331(2):485-495.
84. Byron S.A., et al. Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. Mol. Cancer 2012, 11:75.
85. Morris E.J., et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 2013, 3(7):742-750.
86. Aronov A.M., et al. Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control. J. Med. Chem. 2009, 52(20):6362-6368.
87. Seipelt I., et al. A highly selective Erk1/2 inhibitor with in-vivo anti tumor potency. Cancer Res. 2011, 71(8). (Abstract nr 3563).
88. Ohori M., et al. Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. Biochem. Biophys. Res. Commun. 2005, 336(1):357-363.
89. Bollag G., et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467(7315):596-599.